Rhythm Pharmaceuticals, INC Form 4 insider transactions

Jennifer Kayden Lee, EVP, Head of North America of Rhythm Pharmaceuticals, Inc., sold 75,834 shares of common stock on August 13, 2026 for $117.38 per share.

Yann Mazabraud, EVP, Head of International of Rhythm Pharmaceuticals, Inc., sold 57,000 shares of common stock on August 12, 2026.

Alastair Garfield, Chief Scientific Officer at Rhythm Pharmaceuticals, reported transactions involving common stock and restricted stock units.

Jean Christophe, a Director at Rhythm Pharmaceuticals, Inc., has acquired 4,712 shares of common stock and been granted stock options.

David W.J. McGirr, a Director at Rhythm Pharmaceuticals, Inc., reported transactions involving common stock and equity awards.

Rhythm Pharmaceuticals Director Lynn A. Tetrault reported transactions involving common stock, restricted stock units, and stock options.

Stuart A. Arbuckle, a Director at Rhythm Pharmaceuticals, Inc., reported transactions involving the acquisition and disposition of company common stock and restricted stock units.

Director Jennifer L. Good of Rhythm Pharmaceuticals, Inc. reported transactions involving the acquisition and disposition of company common stock and restricted stock units.

Rhythm Pharmaceuticals Director Lynn A. Tetrault reported a transaction involving the sale of common stock and the exercise of stock options.

Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, Inc., reported significant stock option transactions on May 15, 2026.

Yann Mazabraud, EVP of International at Rhythm Pharmaceuticals, reports transactions involving common stock and restricted stock units.

Kimberly J. Popovits, a Director at Rhythm Pharmaceuticals, acquired stock options and restricted stock units on April 1, 2026.

Rhythm Pharmaceuticals Director Edward T. Mathers' revocable trust received 4,199 shares of common stock through a pro rata distribution from NEA Partners 13, L.P. for no consideration.

Rhythm Pharmaceuticals' Corporate Controller & CAO, Christopher Paul German, exercised stock options and subsequently sold a significant portion of his common stock holdings.

Rhythm Pharmaceuticals' EVP, Head of International, Yann Mazabraud, was granted 35,000 stock options with an exercise price of $94.94.

A director at Rhythm Pharmaceuticals, Edward T. Mathers, reported a change in beneficial ownership through a pro rata stock distribution to his revocable trust.

Rhythm Pharmaceuticals' Corporate Controller and CAO, Christopher Paul German, vested 1,162 restricted stock units and subsequently sold 342 shares to cover tax obligations.

Rhythm Pharmaceuticals' CFO, Hunter C. Smith, exercised 6,099 stock options at $6.8 per share, increasing direct common stock ownership.

Rhythm Pharmaceuticals' Chief Financial Officer, Hunter C. Smith, sold 7,954 shares of common stock in February 2026 under a pre-arranged 10b5-1 trading plan.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, was granted 15,000 restricted stock units and 22,500 stock options.

Rhythm Pharmaceuticals' President and CEO, David P. Meeker, was granted 71,900 restricted stock units and 107,850 stock options on February 11, 2026, as part of his compensation.

Rhythm Pharmaceuticals, Inc. disclosed an equity grant of 23,350 restricted stock units to EVP Yann Mazabraud, vesting over four years.

Rhythm Pharmaceuticals' EVP, Head of North America, Jennifer Kayden Lee, received grants of restricted stock units and stock options.

Rhythm Pharmaceuticals' Corporate Controller & CAO, Christopher Paul German, was granted 5,215 restricted stock units, vesting over four years.

Rhythm Pharmaceuticals' Chief Scientific Officer, Alastair Garfield, received 16,650 Restricted Stock Units and 25,000 stock options on February 11, 2026.

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, received grants of 11,650 restricted stock units and 17,500 stock options.

Rhythm Pharmaceuticals' CFO, Hunter C. Smith, reported sales of common stock under a 10b5-1 plan and received new grants of restricted stock units and stock options.

Rhythm Pharmaceuticals' Chief Financial Officer, Hunter C. Smith, sold 6,628 shares of common stock for approximately $702,819 across multiple transactions in early February 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Rhythm Pharmaceuticals' EVP, Yann Mazabraud, acquired 5,500 shares of common stock through the vesting of restricted stock units.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, reported the vesting of restricted stock units and the acquisition of common stock, with shares withheld for tax obligations.